In order to accommodate growth, make room for more acquisitions and pave the way for the next CEO, Respironics has undergone a realignment of its divisions. John Miclot, Respironics president and CEO, hopes that the changes — which converted the company from having four divisions to three groups centered more closely around its key markets — will enable it to continue to maintain an annual growth rate in the mid-teens by giving some smaller components of the company an opportunity to grow without taking away from its core market. MSNBC (http://msnbc.msn.com/id/9954191/)
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Lax Quality Observed at Device Facility in China
The company failed to investigate a customer complaint about a malfunctioning device.
Three Breast Cancer Drugs Pose Risks of Lung Inflammation, FDA Says
Possible symptoms include shortness of breath while resting or during low physical activity, the agency said.
